Literature DB >> 26880049

Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma.

Norifumi Harimoto1, Tomoharu Yoshizumi1, Masahiro Shimokawa1, Kazuhito Sakata1, Kouichi Kimura1, Shinji Itoh1, Toru Ikegami1, Tetsuo Ikeda1, Ken Shirabe1, Yoshihiko Maehara1.   

Abstract

AIM: The present study investigated the effect of sarcopenia on short- and long-term surgical outcomes and identified potential prognostic factors for hepatocellular carcinoma (HCC) following hepatectomy among patients 70 years of age and older.
METHODS: Patient data were retrospectively collected for 296 consecutive patients who underwent hepatectomy for HCC with curative intent. Patients were assigned to two groups according to age (younger than 70 years, and 70 years and older), and the presence of sarcopenia. The clinicopathological, surgical outcome, and long-term survival data were analyzed.
RESULTS: Sarcopenia was present in 112 of 296 (37.8%) patients with HCC, and 35% of patients aged 70 years and older. Elderly patients had significantly lower serum albumin levels, prognostic nutrition index, percentage of liver cirrhosis, and histological intrahepatic metastasis compared with patients younger than 70 years. Overall survival and disease-free survival rates in patients with sarcopenia correlated with significantly poor prognosis in the group aged 70 years and older. Multivariate analysis revealed that sarcopenia was predictive of an unfavorable prognosis.
CONCLUSION: This retrospective analysis revealed that sarcopenia was predictive of worse overall survival and recurrence-free survival after hepatectomy in patients 70 years of age and older with HCC.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  elderly; hepatectomy; hepatocellular carcinoma; prognosis; sarcopenia

Year:  2016        PMID: 26880049     DOI: 10.1111/hepr.12674

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  38 in total

1.  Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).

Authors:  Shun Sasaki; Eiji Oki; Hiroshi Saeki; Takayuki Shimose; Sanae Sakamoto; Qingjiang Hu; Kensuke Kudo; Yasuo Tsuda; Yuichiro Nakashima; Koji Ando; Yoshito Akagi; Yoshihiro Kakeji; Hideo Baba; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2019-05-06       Impact factor: 3.402

2.  Loss of skeletal muscle mass after curative gastrectomy is a poor prognostic factor.

Authors:  Naruji Kugimiya; Eijiro Harada; Kazuhito Oka; Daichi Kawamura; Yuki Suehiro; Yoshihiro Takemoto; Kimikazu Hamano
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

3.  Sarcopenia predicts poor postoperative outcome in elderly patients with lung cancer.

Authors:  Yo Kawaguchi; Jun Hanaoka; Yasuhiko Ohshio; Keigo Okamoto; Ryosuke Kaku; Kazuki Hayashi; Takuya Shiratori; Makoto Yoden
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-04-10

4.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

5.  Sarcopenia is an independent predictor of complications after colorectal cancer surgery.

Authors:  Ryota Nakanishi; Eiji Oki; Shun Sasaki; Kosuke Hirose; Tomoko Jogo; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Kensuke Kudo; Junji Kurashige; Masahiko Sugiyama; Yuichiro Nakashima; Kippei Ohgaki; Hiroshi Saeki; Yoshihiko Maehara
Journal:  Surg Today       Date:  2017-07-11       Impact factor: 2.549

6.  Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.

Authors:  Yohei Ozawa; Toru Nakano; Yusuke Taniyama; Tadashi Sakurai; Yu Onodera; Kurodo Kamiya; Makoto Hikage; Chiaki Sato; Kai Takaya; Takuro Konno; Michiaki Unno; Takashi Kamei
Journal:  Esophagus       Date:  2019-04-12       Impact factor: 4.230

7.  Preoperative Left Portal Vein Embolization for Left Liver Resection in High-Risk Hepatobiliary Malignancy Patients.

Authors:  Shin Hwang; Gi-Young Ko; Myeong-Hwan Kim; Sung-Koo Lee; Dong-Il Gwon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Do Hyun Park; Sang Soo Lee
Journal:  World J Surg       Date:  2016-11       Impact factor: 3.352

8.  Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?

Authors:  Hiroshi Saeki; Yuichiro Nakashima; Kensuke Kudou; Shun Sasaki; Tomoko Jogo; Kosuke Hirose; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Ryota Nakanishi; Nobuhide Kubo; Koji Ando; Akira Kabashima; Eiji Oki; Yoshihiko Maehara
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

9.  Prognostic Impact of Osteopenia in Patients Who Underwent Living Donor Liver Transplantation for Hepatocellular Carcinoma.

Authors:  Takeo Toshima; Tomoharu Yoshizumi; Yukiko Kosai-Fujimoto; Shoichi Inokuchi; Shohei Yoshiya; Kazuki Takeishi; Shinji Itoh; Noboru Harada; Toru Ikegami; Yuji Soejima; Masaki Mori
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

10.  A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase.

Authors:  Shinkichi Takamori; Gouji Toyokawa; Mototsugu Shimokawa; Fumihiko Kinoshita; Yuka Kozuma; Taichi Matsubara; Naoki Haratake; Takaki Akamine; Fumihiko Hirai; Tetsuzo Tagawa; Yoshinao Oda; Yoshihiko Maehara
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.